Literature DB >> 24027197

A hormone-DNA repair circuit governs the response to genotoxic insult.

Jonathan F Goodwin1, Matthew J Schiewer, Jeffry L Dean, Randy S Schrecengost, Renée de Leeuw, Sumin Han, Teng Ma, Robert B Den, Adam P Dicker, Felix Y Feng, Karen E Knudsen.   

Abstract

UNLABELLED: Alterations in DNA repair promote tumor development, but the impact on tumor progression is poorly understood. Here, discovery of a biochemical circuit linking hormone signaling to DNA repair and therapeutic resistance is reported. Findings show that androgen receptor (AR) activity is induced by DNA damage and promotes expression and activation of a gene expression program governing DNA repair. Subsequent investigation revealed that activated AR promotes resolution of double-strand breaks and resistance to DNA damage both in vitro and in vivo. Mechanistically, DNA-dependent protein kinase catalytic subunit (DNAPKcs) was identified as a key target of AR after damage, controlling AR-mediated DNA repair and cell survival after genotoxic insult. Finally, DNAPKcs was shown to potentiate AR function, consistent with a dual role in both DNA repair and transcriptional regulation. Combined, these studies identify the AR-DNAPKcs circuit as a major effector of DNA repair and therapeutic resistance and establish a new node for therapeutic intervention in advanced disease. SIGNIFICANCE: The present study identifies for the fi rst time a positive feedback circuit linking hormone action to the DNA damage response and shows the significant impact of this process on tumor progression and therapeutic response. These provocative findings provide the foundation for development of novel nodes of therapeutic intervention for advanced disease. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24027197      PMCID: PMC3823813          DOI: 10.1158/2159-8290.CD-13-0108

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  71 in total

1.  Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma.

Authors:  Niamh Lynam-Lennon; John V Reynolds; Graham P Pidgeon; Joanne Lysaght; Laure Marignol; Stephen G Maher
Journal:  Radiat Res       Date:  2010-10-04       Impact factor: 2.841

2.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 3.  Abiraterone in prostate cancer: a new angle to an old problem.

Authors:  Mark N Stein; Susan Goodin; Robert S Dipaola
Journal:  Clin Cancer Res       Date:  2012-03-26       Impact factor: 12.531

Review 4.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

5.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

6.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

7.  Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.

Authors:  Ankur Sharma; Clay E S Comstock; Erik S Knudsen; Khanh H Cao; Janet K Hess-Wilson; Lisa M Morey; Jason Barrera; Karen E Knudsen
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 8.  Overexpression of DNA repair genes is associated with metastasis: a new hypothesis.

Authors:  Alain Sarasin; Audrey Kauffmann
Journal:  Mutat Res       Date:  2008-01-16       Impact factor: 2.433

9.  Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Authors:  Yan Zhao; Huw D Thomas; Michael A Batey; Ian G Cowell; Caroline J Richardson; Roger J Griffin; A Hilary Calvert; David R Newell; Graeme C M Smith; Nicola J Curtin
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

View more
  138 in total

Review 1.  Pharmacological methods to transcriptionally modulate double-strand break DNA repair.

Authors:  Alanna R Kaplan; Peter M Glazer
Journal:  Int Rev Cell Mol Biol       Date:  2019-12-18       Impact factor: 6.813

2.  Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Authors:  Jeremie Calais; Amar U Kishan; Minsong Cao; Wolfgang P Fendler; Matthias Eiber; Ken Herrmann; Francesco Ceci; Robert E Reiter; Matthew B Rettig; John V Hegde; Narek Shaverdian; Chris R King; Michael L Steinberg; Johannes Czernin; Nicholas G Nickols
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

3.  DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Authors:  Jonathan F Goodwin; Vishal Kothari; Justin M Drake; Shuang Zhao; Emanuela Dylgjeri; Jeffry L Dean; Matthew J Schiewer; Christopher McNair; Jennifer K Jones; Alvaro Aytes; Michael S Magee; Adam E Snook; Ziqi Zhu; Robert B Den; Ruth C Birbe; Leonard G Gomella; Nicholas A Graham; Ajay A Vashisht; James A Wohlschlegel; Thomas G Graeber; R Jeffrey Karnes; Mandeep Takhar; Elai Davicioni; Scott A Tomlins; Cory Abate-Shen; Nima Sharifi; Owen N Witte; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

Review 4.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Authors:  Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

Review 5.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

Review 6.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

7.  Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.

Authors:  Daniel E Spratt; Hebert A Vargas; Zachary S Zumsteg; Jennifer S Golia Pernicka; Joseph R Osborne; Xin Pei; Michael J Zelefsky
Journal:  Eur Urol       Date:  2016-08-11       Impact factor: 20.096

Review 8.  Roles for MDC1 in cancer development and treatment.

Authors:  Sophie E Ruff; Susan K Logan; Michael J Garabedian; Tony T Huang
Journal:  DNA Repair (Amst)       Date:  2020-08-11

Review 9.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

10.  Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.

Authors:  Huy Q Ta; Melissa L Ivey; Henry F Frierson; Mark R Conaway; Jaroslaw Dziegielewski; James M Larner; Daniel Gioeli
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.